In addition, in January 2025, Medicare announced it will include semaglutide products (Ozempic, Rybelsus, and Wegovy) in its second round of drug price negotiations, treating all three brands as a single drug due to their shared active ingredient.28 With negotiated prices set to take effect in 2027, this could significantly reduce costs for Medicare beneficiaries
That said, private access can often provide earlier use of new treatments, sometimes years before they reach NHS pathways
This creates an intriguing possibility: GLP-1 therapy might address not just the weight management challenges of Hashimoto's, but also contribute to improving the gut dysfunction that drives the autoimmune process itself
Orforglipron trial data Independent Surveys and Research: Gallup Health and Well-Being Index (October 2025) for obesity rate and GLP-1 usage data
These represent the category with the strongest clinical evidence base for weight management
